Secarna Signs Multiple Agreement with Achilles Therapeutics to Develop Optimized T cell Therapies
Shots:
- Secarna to receive an upfront along with an option exercise fees & is also eligible to receive development & commercial milestone along with royalties on net sales of personalized T cell therapies which are developed & commercialized from the collaboration
- The collaboration will combine Secarnas industry-leading ASO platform, LNAplus with Achilles expertise to develop optimized T cell therapies for cancer patients
- Secarnas LNAplus has proved to be a fast, reliable, scalable & efficient drug discovery platform that contains all aspects of discovery & pre-clinical development & allows the discovery of novel antisense-based therapies against undruggable targets in immune-oncology
Ref: Secarna Pharmaceuticals | Image: Secarna Pharmaceuticals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com